Issue Fragmented approval rules and unsettled strain ownership sit under the transition

Summary

The strategic outlook flags two institutional gaps: approval pathways outside the United States and European Union remain fragmented, slowing commercialization precisely in the markets whose geographic advantage would be largest, and ownership of engineered strains and the licensing terms attached to foundational biological intellectual property are unresolved.